ASEAN Health Screening Market
The ASEAN Health Screening market is expected to reach USD 47,078.82 million by 2031 from USD 17,697.22 million in 2023, growing at a CAGR of 13.5% in the forecast period of 2024 to 2031.
Market Segmentation:
ASEAN health screening market, By Test Type (Cholesterol Tests, Diabetes Test, Cancer Tests, General Check Up Test, STD's, Blood Pressure Test and Others), Application (Cardiovascular Disease, Metabolic Disorders, Oncology, Inflammatory Conditions, Musculoskeletal Disorders, Neurological Conditions, Hepatitis-C Complications, Immunology-Related Conditions, and Others), Panel Type (Multi-Test Panels and Single-Test Panels), Care/Facility (Integrated and Standalone), User (Domestic User and Medical Tourist), Customer Income (Upper Class, Medium Class, and Lower Class), Provider (Hospitals, Clinics, Nursing Facilities, Rehabilitation Centers, Diagnostic Laboratories, and Others), Countries (India, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Cambodia, Brunei, Burma and Laos)-Industry Trends and Forecast to 2031
Overview of ASEAN Health Screening Market Dynamics:
Driver
• Increasing geriatric population
Restrain
• Lack of trained health care professionals
Opportunity
• Technological advancements in health screening
Market Players:
The key market players operating in the ASEAN health screening market are listed below:
• Fullerton Health Corporation Limited (Singapore)
• Mount Alvernia Hospital (Singapore)
• PT Prodia Widyahusada Tbk (Indonesia)
• Raffles Medical Group (Singapore)
• Icon Group (Australia)
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. This publisher does offer titles that are created upon receipt of order.